Wednesday, 18 November 2026European Markets

BIOSENIC Stock Went Down By Over 33% In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 33.33% in 21 sessions from €0.12 to €0.08 at 14:09 EST on Friday, after four consecutive sessions in a row of losses. BEL 20 is rising 0.92% to €3,531.73, after two sequential sessions in a row of gains.

About BIOSENIC

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.

Volume

Today's last reported volume for BIOSENIC is 120752 which is 75.14% below its average volume of 209519.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC's stock is considered to be overbought (>=80).

Volatility

BIOSENIC's last week, last month's, and last quarter's current intraday variation average was a negative 4.63%, a negative 2.45%, and a positive 4.18%.

BIOSENIC's highest amplitude of average volatility was 4.63% (last week), 4.80% (last month), and 4.18% (last quarter).

More news about BIOSENIC (BIOS.BR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 30 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›